Vitamin and supplements maker Blackmores (ASX:BKL) released its Third Quarter Results to the ASX on Tuesday. Group sales for the nine months up to 31 March 2015 came in at $326m, up 28 per cent compared to the previous corresponding period. Net profit after tax (NPAT) for the nine months up to 31 March 2015 came in at $31m, up 76 per cent compared to the previous corresponding period. The numbers were consistent with the investor update released on 30 March 2015. “We are extremely pleased that the momentum in our business has continued,” said chief executive officer Christine Holgate. “This was driven by strong performances across the Group.” The company now expects to post a record full year profit.
Blackmores Australia sales growth came in at 35 per cent. The boost came from strong pharmacy sales and from growing demand for the company’s products from Chinese consumers. Sales in Asia were up 43 per cent, with strong performances in Malaysia, Singapore, China, Hong Kong and Korea. The Australian company was further strengthened by the appointment of Mr. Paul Di Vito as chief marketing officer, the report said. BioCeuticals continued its streak of innovation, according to chief executive Holgate. At its Research Symposium, BioCeuticals attracted more than 350 health care professionals for a three-day conference. There was positive reflection of evidence-based integrative medicine with “overwhelmingly positive participant feedback” regarding the quality of education at the event.
Shares of Blackmores are down 9c, or .15 per cent, at $59.36 per share around 1:56pm on Tuesday. BKL has advanced 128 per cent in the last 12 months and almost 69 per cent so far this year.